Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H13N |
Molecular Weight | 135.2062 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)CC1=CC=CC=C1
InChI
InChIKey=KWTSXDURSIMDCE-QMMMGPOBSA-N
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
Molecular Formula | C9H13N |
Molecular Weight | 135.2062 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017078s048lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdfCurator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf | https://www.drugs.com/ppa/lisdexamfetamine.html | https://www.ncbi.nlm.nih.gov/pubmed/27125257
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017078s048lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf
Curator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf | https://www.drugs.com/ppa/lisdexamfetamine.html | https://www.ncbi.nlm.nih.gov/pubmed/27125257
Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.
Originator
Sources: http://www.chemeurope.com/en/encyclopedia/dextroamphetamine.htmlhttp://adisinsight.springer.com/drugs/800020876
Curator's Comment: New River Pharmaceuticals was bought by Shire Pharmaceuticals
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0050432 |
|||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17239355 |
|||
Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7751968 |
|||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19244097 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VYVANSE Approved UseVYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1) Launch Date2007 |
|||
Primary | VYVANSE Approved UseVYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1) Launch Date2007 |
|||
Primary | DEXEDRINE Approved UseNarcolepsy. Attention Deficit Disorder with Hyperactivity. As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Launch Date1980 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
47.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
24.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36.6 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
431 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 13 - 17 Health Status: unhealthy Age Group: 13 - 17 Sex: M+F Sources: |
Disc. AE: Irritability, Decreased appetite... AEs leading to discontinuation/dose reduction: Irritability (1.3%) Sources: Decreased appetite (0.86%) Insomnia (0.86%) |
1200 mg single, oral Overdose |
healthy, 17 |
Disc. AE: Delirium, Tachycardia... AEs leading to discontinuation/dose reduction: Delirium (acute) Sources: Tachycardia Hypertension Tachypnea Creatine kinase increased (mild) |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 18 - 55 Health Status: unhealthy Age Group: 18 - 55 Sex: M+F Sources: |
Disc. AE: Insomnia, Tachycardia... AEs leading to discontinuation/dose reduction: Insomnia (2%) Sources: Tachycardia (1%) Irritability (1%) Hypertension (1%) Headache (1%) Anxiety (1%) Dyspnea (1%) |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 6 - 12 Health Status: unhealthy Age Group: 6 - 12 Sex: M+F Sources: |
Disc. AE: Ventricular hypertrophy, Tic... AEs leading to discontinuation/dose reduction: Ventricular hypertrophy (1%) Sources: Tic (1%) Vomiting (1%) Psychomotor hyperactivity (1%) Insomnia (1%) Rash (1%) |
30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents Health Status: unhealthy Age Group: adolescents Sources: |
Other AEs: Decreased appetite, Insomnia... Other AEs: Decreased appetite (below serious, 29 patients) Sources: Insomnia (below serious, 7 patients) Weight decreased (below serious, 3 patients) Irritability (below serious, 6 patients) Fatigue (below serious, 4 patients) Nasopharyngitis (below serious, 2 patients) |
20 mg single, oral Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Other AEs: Nausea... |
50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Other AEs: Headache, Nausea... Other AEs: Headache (below serious, 4 patients) Sources: Nausea (below serious, 1 patient) Vomiting (below serious, 2 patients) |
70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Other AEs: Headache, Nausea... Other AEs: Headache (below serious, 2 patients) Sources: Nausea (below serious, 2 patients) |
70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Other AEs: Diarrhea, Dry mouth... Other AEs: Diarrhea (below serious, 6 patients) Sources: Dry mouth (below serious, 25 patients) Fatigue (below serious, 6 patients) Feeling jittery (below serious, 10 patients) Irritability (below serious, 8 patients) Upper respiratory tract infection (below serious, 5 patients) Heart rate increased (below serious, 4 patients) Weight decreased (below serious, 8 patients) Anorexia (below serious, 4 patients) Decreased appetite (below serious, 26 patients) Headache (below serious, 20 patients) Initial insomnia (below serious, 8 patients) Insomnia (below serious, 10 patients) Libido decreased (below serious, 4 patients) Hyperhidrosis (below serious, 5 patients) |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Abuse, Dependence... AEs leading to discontinuation/dose reduction: Abuse Sources: Dependence Cardiovascular disorder (NOS) (grade 3-5) Stroke (serious) Myocardial infarction (serious) Blood pressure increased Heart rate increased Psychiatric symptom NOS Psychotic symptom Manic symptom Growth suppression Vascular disorders Raynaud's phenomenon Serotonin syndrome |
50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Other AEs: Decreased appetite, Dry mouth... Other AEs: Decreased appetite (below serious, 8 patients) Sources: Dry mouth (below serious, 7 patients) Insomnia (below serious, 10 patients) Irritability (below serious, 3 patients) Diaphoresis (below serious, 2 patients) Libido decreased (below serious, 2 patients) Tinnitus (below serious, 2 patients) Muscle tension (below serious, 4 patients) Tachycardia (below serious, 3 patients) Paresthesia (below serious, 2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Decreased appetite | 0.86% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 13 - 17 Health Status: unhealthy Age Group: 13 - 17 Sex: M+F Sources: |
Insomnia | 0.86% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 13 - 17 Health Status: unhealthy Age Group: 13 - 17 Sex: M+F Sources: |
Irritability | 1.3% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 13 - 17 Health Status: unhealthy Age Group: 13 - 17 Sex: M+F Sources: |
Hypertension | Disc. AE | 1200 mg single, oral Overdose |
healthy, 17 |
Tachycardia | Disc. AE | 1200 mg single, oral Overdose |
healthy, 17 |
Tachypnea | Disc. AE | 1200 mg single, oral Overdose |
healthy, 17 |
Delirium | acute Disc. AE |
1200 mg single, oral Overdose |
healthy, 17 |
Creatine kinase increased | mild Disc. AE |
1200 mg single, oral Overdose |
healthy, 17 |
Anxiety | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 18 - 55 Health Status: unhealthy Age Group: 18 - 55 Sex: M+F Sources: |
Dyspnea | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 18 - 55 Health Status: unhealthy Age Group: 18 - 55 Sex: M+F Sources: |
Headache | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 18 - 55 Health Status: unhealthy Age Group: 18 - 55 Sex: M+F Sources: |
Hypertension | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 18 - 55 Health Status: unhealthy Age Group: 18 - 55 Sex: M+F Sources: |
Irritability | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 18 - 55 Health Status: unhealthy Age Group: 18 - 55 Sex: M+F Sources: |
Tachycardia | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 18 - 55 Health Status: unhealthy Age Group: 18 - 55 Sex: M+F Sources: |
Insomnia | 2% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 18 - 55 Health Status: unhealthy Age Group: 18 - 55 Sex: M+F Sources: |
Insomnia | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 6 - 12 Health Status: unhealthy Age Group: 6 - 12 Sex: M+F Sources: |
Psychomotor hyperactivity | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 6 - 12 Health Status: unhealthy Age Group: 6 - 12 Sex: M+F Sources: |
Rash | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 6 - 12 Health Status: unhealthy Age Group: 6 - 12 Sex: M+F Sources: |
Tic | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 6 - 12 Health Status: unhealthy Age Group: 6 - 12 Sex: M+F Sources: |
Ventricular hypertrophy | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 6 - 12 Health Status: unhealthy Age Group: 6 - 12 Sex: M+F Sources: |
Vomiting | 1% Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy, 6 - 12 Health Status: unhealthy Age Group: 6 - 12 Sex: M+F Sources: |
Nasopharyngitis | below serious, 2 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents Health Status: unhealthy Age Group: adolescents Sources: |
Decreased appetite | below serious, 29 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents Health Status: unhealthy Age Group: adolescents Sources: |
Weight decreased | below serious, 3 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents Health Status: unhealthy Age Group: adolescents Sources: |
Fatigue | below serious, 4 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents Health Status: unhealthy Age Group: adolescents Sources: |
Irritability | below serious, 6 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents Health Status: unhealthy Age Group: adolescents Sources: |
Insomnia | below serious, 7 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents Health Status: unhealthy Age Group: adolescents Sources: |
Nausea | below serious, 1 patient | 20 mg single, oral Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Nausea | below serious, 1 patient | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Vomiting | below serious, 2 patients | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Headache | below serious, 4 patients | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Headache | below serious, 2 patients | 70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Nausea | below serious, 2 patients | 70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: |
Feeling jittery | below serious, 10 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Insomnia | below serious, 10 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Headache | below serious, 20 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Dry mouth | below serious, 25 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Decreased appetite | below serious, 26 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Anorexia | below serious, 4 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Heart rate increased | below serious, 4 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Libido decreased | below serious, 4 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Hyperhidrosis | below serious, 5 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Upper respiratory tract infection | below serious, 5 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Diarrhea | below serious, 6 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Fatigue | below serious, 6 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Initial insomnia | below serious, 8 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Irritability | below serious, 8 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Weight decreased | below serious, 8 patients | 70 mg 1 times / day steady, oral Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult |
Abuse | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Blood pressure increased | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Dependence | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Growth suppression | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Heart rate increased | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Manic symptom | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Psychiatric symptom NOS | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Psychotic symptom | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Raynaud's phenomenon | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Serotonin syndrome | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Vascular disorders | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Cardiovascular disorder (NOS) | grade 3-5 Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Myocardial infarction | serious Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Stroke | serious Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Insomnia | below serious, 10 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Diaphoresis | below serious, 2 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Libido decreased | below serious, 2 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Paresthesia | below serious, 2 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Tinnitus | below serious, 2 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Irritability | below serious, 3 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Tachycardia | below serious, 3 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Muscle tension | below serious, 4 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Dry mouth | below serious, 7 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Decreased appetite | below serious, 8 patients | 50 mg 1 times / day steady, oral Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
Page: 7, 78 |
no [Inhibition 87.3 uM] | |||
Page: 7, 78 |
no [Inhibition 89 uM] | |||
Page: 7, 78 |
no [Inhibition 90 uM] | |||
Page: 7, 78 |
no [Inhibition 90.8 uM] | |||
Page: 7, 78 |
no [Inhibition 92.1 uM] | |||
Page: 7, 78 |
no [Inhibition 92.5 uM] | |||
Page: 7, 78 |
no [Inhibition 94.2 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
likely | likely (co-administration study) Comment: Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism; concomitant use of DEXEDRINE and CYP2D6 inhibitors may increase the exposure of DEXEDRINE; Page: 4.0 |
||
Page: 21.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. | 1999 Jun |
|
Neuronal degeneration in the limbic system of weanling rats exposed to saline, hyperthermia or d-amphetamine. | 2000 Dec 8 |
|
Psychostimulants, adult attention deficit hyperactivity disorder and morbid jealousy. | 2000 Feb |
|
Effect of the 5-HT3 receptor antagonist ondansetron on amphetamine-induced hyperactivity and stereotypy in rats. | 2000 Jul |
|
Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study. | 2001 |
|
Stimulation of metabotropic but not ionotropic glutamatergic receptors in the nucleus accumbens is required for the D-amphetamine-induced release of functional dopamine. | 2001 |
|
No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). | 2001 |
|
The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats. | 2001 |
|
Anorectic drugs and pulmonary hypertension from the bedside to the bench. | 2001 Apr |
|
Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells. | 2001 Apr |
|
A nitric oxide-dopamine link pathway in organum vasculosum laminae terminalis of rat brain exerts control over blood pressure. | 2001 Apr |
|
Periodic maternal separation of neonatal rats produces region- and gender-specific effects on biogenic amine content in postmortem adult brain. | 2001 Apr |
|
Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania. | 2001 Feb |
|
Comparison of the effects of infant handling, isolation, and nonhandling on acoustic startle, prepulse inhibition, locomotion, and HPA activity in the adult rat. | 2001 Feb |
|
Conditioned activity to amphetamine in transgenic mice expressing an antisense RNA against the glucocorticoid receptor. | 2001 Feb |
|
The reverse transport of DA, what physiological significance? | 2001 Feb |
|
Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. | 2001 Feb 15 |
|
Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. | 2001 Feb 16 |
|
Selective inhibition of amine oxidases differently potentiate the hypophagic effect of benzylamine in mice. | 2001 Feb 9 |
|
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. | 2001 Jan |
|
Environmental novelty differentially affects c-fos mRNA expression induced by amphetamine or cocaine in subregions of the bed nucleus of the stria terminalis and amygdala. | 2001 Jan 15 |
|
Behavioral activation in rats requires endogenous ascorbate release in striatum. | 2001 Jan 15 |
|
Neonatal dexamethasone on day 7 in rats causes behavioral alterations reflective of hippocampal, but not cerebellar, deficits. | 2001 Jan-Feb |
|
Computer-aided screening for hallucinogenic and stimulant amphetamines with gas chromatography-Fourier transform infrared spectroscopy (GC-FTIR). | 2001 Jan-Feb |
|
Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes. | 2001 Mar |
|
Adrenergic hyperactivity and metanephrine excess in the nucleus accumbens after prefrontocortical dopamine depletion. | 2001 Mar |
|
Acute myocardial infarction associated with amphetamine use. | 2001 Mar |
|
Seizure activity and hyperthermia potentiate the increases in dopamine and serotonin extracellular levels in the amygdala during exposure to d-amphetamine. | 2001 Mar |
|
Previous exposure to amphetamine enhances the subsequent locomotor response to a D1 dopamine receptor agonist when glutamate reuptake is inhibited. | 2001 Mar 1 |
|
Dopaminergic role in stimulant-induced wakefulness. | 2001 Mar 1 |
|
Differential effects of endomorphin-1 and -2 on amphetamine sensitization: neurochemical and behavioral aspects. | 2001 Mar 1 |
|
Sexual behavior induction of c-Fos in the nucleus accumbens and amphetamine-stimulated locomotor activity are sensitized by previous sexual experience in female Syrian hamsters. | 2001 Mar 15 |
|
Dissociations between the effects of intra-accumbens administration of amphetamine and exposure to a novel environment on accumbens dopamine and cortical acetylcholine release. | 2001 Mar 16 |
|
Serotonin transporter localization in the hamster suprachiasmatic nucleus. | 2001 Mar 2 |
|
Amphetamine-stimulated cortical acetylcholine release: role of the basal forebrain. | 2001 Mar 9 |
|
Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. | 2001 May |
|
The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. | 2001 May |
|
Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. | 2001 May 1 |
|
Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. | 2008 Mar |
|
Alopecia following initiation of lisdexamfetamine in a pediatric patient. | 2009 |
|
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine. | 2009 |
|
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. | 2010 |
|
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. | 2010 Jun 24 |
|
New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children. | 2010 May 25 |
|
Use of psychostimulants in patients with dementia. | 2010 Oct |
Sample Use Guides
Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, DEXEDRINE may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. SPANSULE capsules may be used for once-a-day dosage wherever appropriate.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6428136
Curator's Comment: The action of several concentrations of d-amphetamine on the NADH-tetrazolium reductase histochemical reaction has been studied in several nervous regions of rats. The facts observed have demonstrated that d-amphetamine increases the intensity of the histochemical reaction by its action on NADH-oxido-reductase activity in all nervous regions studied.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:59 GMT 2025
by
admin
on
Mon Mar 31 17:49:59 GMT 2025
|
Record UNII |
TZ47U051FI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN06BA02
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
CFR |
21 CFR 310.502
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
WHO-ATC |
N06BA02
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
NDF-RT |
N0000175739
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
EPA PESTICIDE CODE |
600005
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
LIVERTOX |
293
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
NDF-RT |
N0000175729
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3288
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID8022907
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
TZ47U051FI
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
51-64-9
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
73713
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
4469
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
1430
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
841
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL612
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
TZ47U051FI
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
Dextroamphetamine
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
SUB07019MIG
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
100000088421
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
DB01576
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
DEXTROAMPHETAMINE
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
5826
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
200-112-1
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
m4226
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
2147
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
D003913
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
C28981
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
3055
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT | |||
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
Adult PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||